Editas Medicine provides update, to reduce headcount by approximately 20%

Editas Medicine announced a strategic update, including portfolio reprioritization and research and development realignment. The Company’s R&D efforts will narrow, focusing on hemoglobinopathies and in vivo discovery, as Editas Medicine will pursue and develop programs it believes have maximum probabilities of technical, regulatory, and commercial success. As a result of the strategic reprioritization, Editas Medicine’s headcount is being reduced by approximately 20%, which is expected to extend the Company’s cash runway into 2025. Editas Medicine’s strategic changes include: Prioritizing resource allocation towards EDIT-301, the Company’s lead clinical program for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia. Discontinuing internal investments in the Company’s inherited retinal disease programs, including EDIT-101 for Leber Congenital Amaurosis 10 and EDIT-103 for rhodopsin-associated autosomal dominant retinitis pigmentosa. Editas Medicine will seek partnerships for further development of its IRD programs. Discontinuing internal investments in the Company’s wholly owned multiplexed edited induced pluripotent stem cell derived natural killer cell programs, including EDIT-202 for solid tumors. Editas Medicine will seek a partnership to continue development of the Company’s iNK franchise. Restructuring the Company’s research organization into two divisions: Drug Discovery for in vivo target identification, therapeutic asset creation, and translational research. Advanced Technology for in vivo targeted integration and targeted delivery. Developing milder patient preconditioning regimens for hematopoietic stem cell transplants. Developing next generation in vivo medicines, including in vivo editing of HSCs and other tissues. Editas Medicine will continue advancing its cellular therapy assets through partnerships, including continued development of alpha-beta T-cell medicines with Bristol-Myers-Squibb and gamma-delta T-cell medicines with Immatics N.V. The Company will also continue assessing additional collaboration opportunities to license Editas Medicine’s intellectual property and proprietary technology.